Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, Odense 5230, Denmark; Pharmaceutical R&D, F. Hoffmann-La Roche Ltd., Basel 4070, Switzerland.
Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, Odense 5230, Denmark.
Eur J Pharm Sci. 2023 Sep 1;188:106533. doi: 10.1016/j.ejps.2023.106533. Epub 2023 Jul 20.
Many novel small drug molecules are poorly water-soluble and thus, enabling drug formulations may be required to ensure sufficient absorption upon oral administration. Biopharmaceutical assessment and absorption prediction of enabling formulations, however, remains challenging. Combined in vitro dissolution/permeation (D/P) assays have gained increasing interest since they may provide a more realistic formulation ranking based on the drug permeation profiles from different formulations as compared to conventional dissolution, which captures both readily permeable and not readily permeable fractions of "dissolved" drug. Moreover, the combined in vitro D/P assays allow to better predict intestinal supersaturation and precipitation processes as compared to simple dissolution setups due to the effect of an absorptive sink. Microdialysis on the other hand has proven useful to determine molecularly dissolved drug in colloidal dispersions, thus allowing for a deeper mechanistic insight into the mechanism of drug release from supersaturating formulations. Here, microdialysis sampling from the donor compartment was used in combination with the dissolution/permeation (D/P) tool PermeaLoop™ to study commercial supersaturating drug formulations of the poorly soluble and weakly basic drug Posaconazole (PCZ). An amorphous solid dispersion (ASD)-based tablet, as well as a crystalline suspension in acidified and neutral dilution medium, respectively, were tested. Microdialysis sampling allowed for differentiation between molecularly dissolved and micellar drug concentration, as expected, but, surprisingly, it was found that the presence of the microdialysis probe affected the precipitation behavior of a crystalline suspension within the two-stage D/P setup, simulating the oral administration of the acidified PCZ (Noxafil®) suspension: the extent and duration of supersaturation in the donor decreased significantly, which also affected permeation. Similarly, for the ASD-based tablet, a less pronounced supersaturation was observed during the first 120 min of the experiment. Hence, in this case, the formulation ranking and the prediction of intestinal supersaturation in the in vitro D/P assay became less predictive as compared to a conventional PermeaLoop™ study without microdialysis sampling. It was concluded that valuable mechanistic insights into the molecularly dissolved drug profiles over time can be obtained by microdialysis. However, since the presence of the probe may affect the degree of supersaturation and precipitation, a conventional D/P assay (without microdialysis sampling) is preferred for formulation ranking of supersaturating drug formulations.
许多新型小分子药物的水溶性较差,因此需要使药物制剂化以确保口服给药时的充分吸收。然而,使能制剂的生物药剂学评估和吸收预测仍然具有挑战性。体外溶解/渗透(D/P)联合测定法越来越受到关注,因为与仅捕获“溶解”药物中易渗透和不易渗透部分的常规溶解相比,它们可以基于不同制剂的药物渗透谱提供更真实的制剂排序。此外,由于吸收性汇的影响,与简单的溶解设置相比,体外 D/P 联合测定法允许更好地预测肠过饱和和沉淀过程。另一方面,微透析已被证明可用于确定胶体分散体中分子溶解的药物,从而可以更深入地了解过饱和制剂中药物释放的机制。在这里,从供体室进行微透析采样,并与溶解/渗透(D/P)工具 PermeaLoop™结合使用,研究了难溶性和弱碱性药物泊沙康唑(PCZ)的商业过饱和药物制剂。分别测试了基于无定形固体分散体(ASD)的片剂和酸化及中性稀释介质中的结晶混悬剂。微透析采样允许区分分子溶解和胶束药物浓度,这是预期的,但令人惊讶的是,发现微透析探针的存在会影响在模拟酸化 PCZ(Noxafil®)混悬剂口服给药的两阶段 D/P 装置中结晶混悬剂的沉淀行为:供体中的过饱和度程度和持续时间显著降低,这也影响了渗透。同样,对于基于 ASD 的片剂,在实验的前 120 分钟内观察到的过饱和度较低。因此,在这种情况下,与没有微透析采样的传统 PermeaLoop™研究相比,制剂排序和体外 D/P 测定中的肠过饱和度预测变得不那么具有预测性。结论是,通过微透析可以获得随时间推移的分子溶解药物谱的有价值的机制见解。然而,由于探针的存在可能会影响过饱和度和沉淀的程度,因此对于过饱和药物制剂的制剂排序,优选使用传统的 D/P 测定法(不进行微透析采样)。